Antithrombotics in Acute Coronary Syndromes

Journal of the American College of Cardiology

Volumn 54, Issue 11, 2009, Pages 969-984

  Bonaca, Marc P ^a   Steg, Philippe Gabriel ^b   Feldman, Laurent J ^b   Canales, John F ^c   Ferguson, James J ^c,d   Wallentin, Lars ^e   Califf, Robert M ^f   Harrington, Robert A ^f   Giugliano, Robert P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BICHAT HOSPITAL   (France)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UPPSALA UNIVERSITY   (Sweden)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anticoagulant; antiplatelet; antithrombotic; infarction; ischemia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CANGRELOR; CLOPIDOGREL; DU 176B; EDOXABAN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; LY 5157117; METOPROLOL; OTAMIXABAN; PLACEBO; PRASUGREL; RETEPLASE; RIVAROXABAN; THROMBIN INHIBITOR; TICAGRELOR; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; WAROXABAN; XIMELAGATRAN; YM 150;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; BLEEDING; CLINICAL TRIAL; COMORBIDITY; CONSERVATIVE TREATMENT; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; INVASIVE PROCEDURE; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; MEDICAL RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; FACTOR XA; HUMANS; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBIN;

EID: 69249225639     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.03.083     Document Type: Review

References (98)

1. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 50 (2007) e1-e157
2. Antman E.M., Hand M., Armstrong P.W., et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee. J Am Coll Cardiol 51 (2008) 210-247
3. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47 (2006) e1-e121
4. Silber S., Albertsson P., Aviles F.F., et al. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 26 (2005) 804-847
5. Bassand J.P., Hamm C.W., Ardissino D., et al., Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28 (2007) 1598-1660
6. Van de Werf F., Ardissino D., Betriu A., et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29 (2008) 2909-2945
7. Kastrati A., Mehilli J., Neumann F.J., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295 (2006) 1531-1538
8. Ndrepepa G., Kastrati A., Mehilli J., et al. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. Eur Heart J 29 (2008) 455-461
9. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
10. Stone G.W., Bertrand M.E., Moses J.W., et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 297 (2007) 591-602
11. Mahaffey K.W., and Harrington R.A. Optimal timing for use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: questions, answers, and more questions. JAMA 297 (2007) 636-639
12. Waksman R. ACUITY-PCI: one drug does not fit all. Lancet 369 (2007) 881-882
13. Bolognese L., Falsini G., Liistro F., et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol 47 (2006) 522-528
14. Giugliano R.P., White J.A., Bode C., et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 360 (2009) 2176-2190
15. Montalescot G., Antoniucci D., Kastrati A., et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 28 (2007) 443-449
16. Ellis S.G., Tendera M., de Belder M.A., et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 358 (2008) 2205-2217
17. Van't Hof A.W., Ten Berg J., Heestermans T., et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 372 (2008) 537-546
18. Alexander K.P., Chen A.Y., Roe M.T., et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005) 3108-3116
19. Kirtane A.J., Piazza G., Murphy S.A., et al. Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol 47 (2006) 2374-2379
20. Bhatt D.L., and Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2 (2003) 15-28
21. Bertrand M.E., Rupprecht H.J., Urban P., and Gershlick A.H. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102 (2000) 624-629
22. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
23. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
24. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
25. Chen Z.M., Jiang L.X., Chen Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
26. Steinhubl S.R., Berger P.B., Brennan D.M., and Topol E.J. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 47 (2006) 939-943
27. Montalescot G., Sideris G., Meuleman C., et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 48 (2006) 931-938
28. Cuisset T., Frere C., Quilici J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48 (2006) 1339-1345
29. Mehta S.R. Clopidogrel in non-ST-segment elevation acute coronary syndromes. Eur Heart J Suppl 8 (2006) G25-G30
30. Mehta R.H., Roe M.T., Mulgund J., et al. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol 48 (2006) 281-286
31. Serebruany V.L., Steinhubl S.R., Berger P.B., Malinin A.I., Bhatt D.L., and Topol E.J. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45 (2005) 246-251
32. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2009) 354-362
33. Gilard M., Arnaud B., Le Gal G., Abgrall J.F., and Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 4 (2006) 2508-2509
34. Ho P.M., Maddox T.M., Wang L., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301 (2009) 937-944
35. Bhatt D.L., Scheiman J., Abraham N.S., et al., American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 52 (2008) 1502-1517
36. Sibbing D., Braun S., Morath T., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53 (2009) 849-856
37. Ajzenberg N., Aubry P., Huisse M.G., et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol 45 (2005) 1753-1756
38. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49 (2007) 2312-2317
39. Bonello L., Camoin-Jau L., Armero S., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 103 (2009) 5-10
40. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
41. Brandt J.T., Payne C.D., Wiviott S.D., et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153 (2007) 66.e9-66.e16
42. Jernberg T., Payne C.D., Winters K.J., et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 27 (2006) 1166-1173
43. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
44. Tantry U.S., Bliden K.P., and Gurbel P.A. Azd6140. Expert Opin Investig Drugs 16 (2007) 225-229
45. Husted S., Emanuelsson H., Heptinstall S., Sandset P.M., Wickens M., and Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27 (2006) 1038-1047
46. Cannon C.P., Husted S., Harrington R.A., et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50 (2007) 1844-1851
47. AstraZeneca Announces Top Line Results From Pivotal Phase III Study for BRILINTA. Available at: http://www.astrazeneca.com/media/latest-press-releases/brilinta-plato?it emId=5837126. Accessed August 2, 2009.
48. Storey R.F. The P2Y12 receptor as a therapeutic target in cardiovascular disease. Platelets 12 (2001) 197-209
49. Greenbaum A.B., Grines C.L., Bittl J.A., et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 151 (2006) 689e1-10
50. Fugate S.E., and Cudd L.A. Cangrelor for treatment of coronary thrombosis. Ann Pharmacother 40 (2006) 925-930
51. The Medicines Company Discontinues Phase 3 CHAMPION Clinical Trial Program of Cangrelor. Available at: http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol-news Article&ID=1287788&highlight=. Accessed August 2, 2009.
52. Becker R.C., Moliterno D.J., Jennings L., et al. A platelet thrombin receptor-1 antagonist for patients undergoing non-urgent percutaneous coronary intervention. Lancet 373 (2009) 1919-1928
53. Weitz J.I. Low-molecular-weight heparins [erratum in N Engl J Med 1997;337:1567]. N Engl J Med 337 (1997) 688-698
54. Antman E.M., Cohen M., Radley D., et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 100 (1999) 1602-1608
55. Bhandari M., Hirsh J., Weitz J.I., Young E., Venner T.J., and Shaughnessy S.G. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost 80 (1998) 413-417
56. Fox K.A., Antman E.M., Montalescot G., et al. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 49 (2007) 2249-2255
57. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 188S-203S
58. Eikelboom J.W., Anand S.S., Malmberg K., Weitz J.I., Ginsberg J.S., and Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 355 (2000) 1936-1942
59. Cohen M., Theroux P., Borzak S., et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J 144 (2002) 470-477
60. Ferguson J.J., Antman E.M., Bates E.R., et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J 146 (2003) 628-634
61. Goodman S.G., Fitchett D., Armstrong P.W., Tan M., and Langer A. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 107 (2003) 238-244
62. Blazing M.A., de Lemos J.A., White H.D., et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 292 (2004) 55-64
63. Ferguson J.J., Califf R.M., Antman E.M., et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292 (2004) 45-54
64. Drouet L., Bal dit Sollier C., and Martin J. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study. Am Heart J 158 (2009) 177-184
65. Bhatt D.L., Lee B.I., Casterella P.J., et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single Bolus Enoxaparin Study. J Am Coll Cardiol 41 (2003) 20-25
66. Kereiakes D.J., Grines C., Fry E., et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 13 (2001) 272-278
67. Montalescot G., White H.D., Gallo R., et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 355 (2006) 1006-1017
68. Antman E.M., Morrow D.A., McCabe C.H., et al., ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354 (2006) 1477-1488
69. Gibson C.M., Murphy S.A., Montalescot G., et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 49 (2007) 2238-2246
70. Petersen J.L., Mahaffey K.W., Hasselblad V., et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA 292 (2004) 89-96
71. Di Nisio M., Middeldorp S., and Buller H.R. Direct thrombin inhibitors. N Engl J Med 353 (2005) 1028-1040
72. Bates S.M., and Weitz J.I. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol 82 (1998) 12P-18P
73. Xiao Z., and Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97 (1998) 251-256
74. Maraganore J.M., and Adelman B.A. Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Coron Artery Dis 7 (1996) 438-448
75. Direct thrombin inhibitors in acute coronary syndromes. principal results of a meta-analysis based on individual patients' data. Lancet 359 (2002) 294-302
76. Lincoff A.M., Bittl J.A., Harrington R.A., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
77. Diamond G.A., and Kaul S. An Orwellian discourse on the meaning and measurement of noninferiority. Am J Cardiol 99 (2007) 284-287
78. Stone G.W., Witzenbichler B., Guagliumi G., et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358 (2008) 2218-2230
79. Popma J.J., Berger P., Ohman E.M., Harrington R.A., Grines C., and Weitz J.I. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 576S-599S
80. White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 358 (2001) 1855-1863
81. U.S. Food and Drug Administration Web site. Cardiovascular and Renal Advisory Committee Web page. Clinical review. Integrated executive summary of FDA review for NDA 21-686 Exanta (Ximelegatran) (2007). http://www.fda.gov/ohrms/dockets/AC/04/briefing/2004-4069B1_03_FDA-Backg rounder-Execsummaryredacted.pdf Accessed August 2, 2009
82. Eriksson B.I., Dahl O.E., Buller H.R., et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 3 (2005) 103-111
83. Bauer K.A. Fondaparinux: a new synthetic and selective inhibitor of factor Xa. Best Pract Res Clin Haematol 17 (2004) 89-104
84. Tan K.T., and Lip G.Y. Fondaparinux. Curr Pharm Des 11 (2005) 415-419
85. Yusuf S., Mehta S.R., Chrolavicius S., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006) 1464-1476
86. Yusuf S., Mehta S.R., Chrolavicius S., et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295 (2006) 1519-1530
87. Cohen M., Bhatt D.L., Alexander J.H., et al. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 115 (2007) 2642-2651
88. Giugliano R.P., Rohatagi S., Kastrissios H., et al. The relationship between the oral factor Xa inhibitor edoxaban (DU-176b) pharmacokinetics and the probability of bleeding events in patients with non-valvular atrial fibrillation: Presented at: ISTH Scientific Sessions; Boston, MA; July 15 (2009)
89. Alexander J.H., Becker R.C., Bhatt D.L., et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119 (2009) 2877-2885
90. Mega J.L., Braunwald E., Mohanavelu S., et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374 (2009) 29-38
91. Agnelli G., Haas S., Ginsberg J.S., Krueger K.A., Dmitrienko A., and Brandt J.T. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 5 (2007) 746-753
92. Eriksson B.I., Turpie A.G., Lassen M.R., et al. YM150, an oral direct Factor Xa inhibitor, as prophylaxis for venous thromboembolism in patients with elective primary hip replacement surgery: a dose escalation study (abstr). Blood 104 Suppl (2005) 813
93. Weitz J.I., and Linkins L.A. Beyond heparin and warfarin: the new generation of anticoagulants. Expert Opin Invest Drugs 16 (2007) 271-282
94. Morrow D.A., Murphy S.A., McCabe C.H., Mackman N., Wong H.C., and Antman E.M. Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. Eur Heart J 26 (2005) 682-688
95. Giugliano R.P., Wiviott S.D., Stone P.H., et al. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J Am Coll Cardiol 49 (2007) 2398-2407
96. Dyke C.K., Steinhubl S.R., Kleiman N.S., et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114 (2006) 2490-2497
97. Nimjee S.M., Rusconi C.P., Harrington R.A., and Sullenger B.A. The potential of aptamers as anticoagulants. Trends Cardiovasc Med 15 (2005) 41-45
98. Greenberg H., Raymond S.U., and Leeder S.R. Cardiovascular disease and global health: threat and opportunity. Health Aff (Millwood) Suppl Web Exclusives (2005) W-5-31-41